John Heit

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q
    J A Heit
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Thromb Haemost 10:1521-31. 2012
  2. pmc Predicting the risk of venous thromboembolism recurrence
    John A Heit
    Division of Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:S63-7. 2012
  3. ncbi request reprint Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study
    J A Heit
    Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Intern Med 159:445-53. 1999
  4. pmc The epidemiology of venous thromboembolism in the community
    John A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arterioscler Thromb Vasc Biol 28:370-2. 2008
  5. ncbi request reprint The epidemiology of venous thromboembolism in the community: implications for prevention and management
    John A Heit
    Coagulation Laboratories and Clinic, Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Thromb Thrombolysis 21:23-9. 2006
  6. ncbi request reprint The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism
    John A Heit
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Chest 124:40S-8S. 2003
  7. ncbi request reprint Cancer and venous thromboembolism: scope of the problem
    John A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer Control 12:5-10. 2005
  8. ncbi request reprint Venous thromboembolism: disease burden, outcomes and risk factors
    J A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 3:1611-7. 2005
  9. ncbi request reprint Familial segregation of venous thromboembolism
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 2:731-6. 2004
  10. ncbi request reprint Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study
    John A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MI, USA
    J Thromb Haemost 3:710-7. 2005

Detail Information

Publications60

  1. pmc A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q
    J A Heit
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Thromb Haemost 10:1521-31. 2012
    ..To identify venous thromboembolism (VTE) disease-susceptibility genes...
  2. pmc Predicting the risk of venous thromboembolism recurrence
    John A Heit
    Division of Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:S63-7. 2012
    ..The appropriateness of secondary prophylaxis should be continuously reevaluated, and the prophylaxis stopped if the benefit no longer exceeds the risk...
  3. ncbi request reprint Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study
    J A Heit
    Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Intern Med 159:445-53. 1999
    ....
  4. pmc The epidemiology of venous thromboembolism in the community
    John A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arterioscler Thromb Vasc Biol 28:370-2. 2008
  5. ncbi request reprint The epidemiology of venous thromboembolism in the community: implications for prevention and management
    John A Heit
    Coagulation Laboratories and Clinic, Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Thromb Thrombolysis 21:23-9. 2006
    ..Better individual risk stratification is needed in order to modify exposures and target primary and secondary prophylaxis to the person who would benefit most...
  6. ncbi request reprint The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism
    John A Heit
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Chest 124:40S-8S. 2003
    ..Oral direct thrombin inhibitors may also be safe and effective, and offer enhanced convenience without diet or drug-drug interactions...
  7. ncbi request reprint Cancer and venous thromboembolism: scope of the problem
    John A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer Control 12:5-10. 2005
  8. ncbi request reprint Venous thromboembolism: disease burden, outcomes and risk factors
    J A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 3:1611-7. 2005
    ..Better individual risk stratification is needed in order to modify exposures and target primary and secondary prophylaxis to the person who would benefit most...
  9. ncbi request reprint Familial segregation of venous thromboembolism
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thromb Haemost 2:731-6. 2004
    ..Venous thromboembolism (VTE) is postulated as a complex disease, but the heritability and mode of inheritance are uncertain...
  10. ncbi request reprint Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study
    John A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MI, USA
    J Thromb Haemost 3:710-7. 2005
    ..Null genetic marker allele frequencies did not differ significantly among cases and controls. We conclude that polymorphisms or haplotypes within the TM gene are not common risk factors for incident VTE...
  11. doi request reprint Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study
    John A Heit
    Mayo Clinic Thrombophilia Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:467-71. 2010
    ..The prevalence of transient VTE risk factors and idiopathic VTE among Blacks appears to be lower and higher, respectively, suggesting that heritability may be important in the etiology of VTE among Black-Americans...
  12. ncbi request reprint Mapping out the future in venous thromboembolism and acute coronary syndromes
    John A Heit
    Division of Cardiovascular Diseases, Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Semin Thromb Hemost 28:33-9. 2002
    ....
  13. ncbi request reprint Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Intern Med 160:761-8. 2000
    ..The appropriate duration of oral anticoagulation after a first episode of venous thromboembolism (VTE) is uncertain and depends upon VTE recurrence rates...
  14. ncbi request reprint Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Arch Intern Med 160:809-15. 2000
    ..Reported risk factors for venous thromboembolism (VTE) vary widely, and the magnitude and independence of each are uncertain...
  15. ncbi request reprint Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study
    J A Heit
    Division of Cardiovascular Diseases, Section of Vascular Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Vasc Surg 33:1022-7. 2001
    ..The incidence rates of venous stasis syndrome and venous ulcer are uncertain, and trends in incidence are unknown...
  16. ncbi request reprint Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement
    J A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, and the Division of Hematology Section of Hematology Research, Department of Internal Medicine Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Thromb Res 101:V163-73. 2001
    ..Future research should be directed at identifying patients at risk for out-of-hospital venous thromboembolism, and targeting extended prophylaxis to those at highest risk...
  17. ncbi request reprint The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study
    J A Heit
    Division of Cardiovascular Diseases and Section of Haematology Research, Department of Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    J Thromb Haemost 3:305-11. 2005
    ..Among all carriers, those > or = 60 years old are at the highest risk for VTE. The incidence of VTE among asymptomatic women carriers during pregnancy is low and insufficient to warrant prophylaxis...
  18. ncbi request reprint The epidemiology of venous thromboembolism in the community
    J A Heit
    Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Thromb Haemost 86:452-63. 2001
    ..To reduce venous thromboembolism incidence, improve survival, and prevent recurrence and complications, patients with these characteristics should receive appropriate prophylaxis...
  19. pmc Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism
    J A Heit
    Division of Cardiovascular Diseases, Department of Internal Medicine Division of Experimental Pathology, Department of Laboratory Medicine and Pathology Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    J Thromb Haemost 9:1133-42. 2011
    ..40. Conclusions: Anticoagulant, procoagulant, fibrinolytic and innate immunity pathway genetic variation accounts for a large proportion of VTE among non-Hispanic adults of European ancestry...
  20. pmc Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study
    John A Heit
    Division of Cardiovascular Diseases Section of Vascular Diseases, Mayo Clinic, Rochester, MN, USA
    Blood 118:4992-9. 2011
    ..In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence...
  21. ncbi request reprint Outcomes after withholding anticoagulation from patients with suspected acute pulmonary embolism and negative computed tomographic findings: a cohort study
    Stephen J Swensen
    Department of Radiology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:130-8. 2002
    ..To determine the outcome of withholding anticoagulation from patients with suspected acute pulmonary embolism in whom computed tomographic (CT) findings are interpreted as negative for pulmonary embolism...
  22. pmc Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study
    John A Heit
    Division of Cardiovascular Diseases, Section of Vascular Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 29:1399-405. 2009
    ..Consequently, we tested diabetes for an independent association with incident VTE...
  23. doi request reprint Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients
    Paul R Daniels
    Mayo Clinic Thrombophilia Center, Gonda Vascular Center, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Thromb Res 124:300-5. 2009
    ....
  24. ncbi request reprint Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study
    John A Heit
    Hematology Research, Stabile 660, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Intern Med 162:1245-8. 2002
    ....
  25. ncbi request reprint Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study
    John A Heit
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 143:697-706. 2005
    ..The risk for venous thromboembolism during pregnancy or postpartum is uncertain...
  26. doi request reprint Periprocedural anticoagulation management of patients with venous thromboembolism
    Robert D McBane
    Gonda Thrombophilia Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Arterioscler Thromb Vasc Biol 30:442-8. 2010
    ..The incidence of thromboembolism and bleeding related to periprocedural anticoagulation management of such patients is unknown...
  27. doi request reprint Estrogen, inflammation, and platelet phenotype
    Virginia M Miller
    Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gend Med 5:S91-S102. 2008
    ..Although exogenous estrogenic therapies increase the risk of thrombosis, the effects of estrogen on formed elements of blood are uncertain...
  28. doi request reprint Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation
    Waldemar E Wysokinski
    Thrombophilia Clinic, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:639-45. 2008
    ....
  29. pmc Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women
    Muthuvel Jayachandran
    Department of Surgery and Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, USA
    Am J Physiol Heart Circ Physiol 295:H931-H938. 2008
    ..Therefore, the characterization of platelet and endothelial microparticles may identify early menopausal women with premature CAC who would not otherwise be identified by the usual risk factor analysis...
  30. doi request reprint Incidence and cost burden of post-thrombotic syndrome
    Aneel A Ashrani
    Division of Hematology, Department of Internal Medicine, Stabile 6 60, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA
    J Thromb Thrombolysis 28:465-76. 2009
    ..Increasing the awareness of PTS, and the methods to prevent this complication may help reduce its incidence, improve long-term outcomes in patients, and decrease resulting costs associated with treatment...
  31. doi request reprint Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature
    Mischelle A Elliott
    Department of Internal Medicine Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Haematol 83:365-72. 2009
    ..Prospective studies are urgently needed to define the true efficacy and long-term safety of rituximab...
  32. pmc Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case-control study
    Aneel A Ashrani
    Division of Hematology, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Vasc Med 14:339-49. 2009
    ....
  33. ncbi request reprint Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition)
    Terese T Horlocker
    Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA
    Reg Anesth Pain Med 35:64-101. 2010
    ..These are based on case reports, clinical series, pharmacology,hematology, and risk factors for surgical bleeding. An understanding of the complexity of this issue is essential to patient management...
  34. ncbi request reprint Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study
    Irene Meissner
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 47:440-5. 2006
    ..We sought to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA), and stroke prospectively in a unselected population sample...
  35. doi request reprint Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration
    Michelle A Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 85:43-50. 2010
    ..Recognition of cancer-associated microangiopathic hemolytic anemia with thrombocytopenia (CA-MHA) is paramount to avoid inappropriate PE therapy and delays in cancer-specific chemotherapy...
  36. pmc Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: a nested case-control study
    Aneel A Ashrani
    Division of Hematology, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Vasc Med 15:387-97. 2010
    ..VOO and VTE are associated with impaired ADL. We hypothesize that rapid clearance of venous outflow obstruction in individuals with acute VTE will improve their QoL and ADL...
  37. ncbi request reprint Risk factors for venous thromboembolism in nursing home residents
    Cynthia L Liebson
    Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:151-7. 2008
    ..To determine risk factors for venous thromboembolism (VTE) among nursing home (NH) residents...
  38. doi request reprint Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohort
    Cynthia L Leibson
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester 55905, Minnesota, USA
    Med Care 46:127-32. 2008
    ..We estimated sensitivity, specificity, PPV, and negative predictive value (NPV) of claims-based approaches using the Rochester Epidemiology Project (REP) venous thromboembolism (VTE) cohort as a "gold standard."..
  39. ncbi request reprint Estrogen therapy and thrombotic risk
    Virginia M Miller
    Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, United States
    Pharmacol Ther 111:792-807. 2006
    ....
  40. ncbi request reprint Sensitivity and specificity of the semiquantitative latex agglutination D-dimer assay for the diagnosis of acute pulmonary embolism as defined by computed tomographic angiography
    David A Froehling
    Division of Area General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:164-8. 2004
    ....
  41. ncbi request reprint Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin
    Michelle A Elliott
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 45:1545-9. 2004
    ..021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions...
  42. ncbi request reprint Evaluation of a quantitative D-dimer latex immunoassay for acute pulmonary embolism diagnosed by computed tomographic angiography
    David A Froehling
    Division of General Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:556-60. 2007
    ..To determine the sensitivity and specificity of a quantitative plasma fibrin D-dimer latex immunoassay (LIA) for the diagnosis of acute pulmonary embolism...
  43. ncbi request reprint Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)
    Terese T Horlocker
    Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Reg Anesth Pain Med 28:172-97. 2003
  44. ncbi request reprint Venous stasis syndrome: the long-term burden of deep vein thrombosis
    John A Heit
    Mayo Clinic Thrombophilia Center, Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Hosp Med 64:593-8. 2003
    ..Prophylaxis with anticoagulant agents, including new drugs presently under investigation, may decrease the incidence and costs associated with this condition...
  45. pmc Warfarin sensitivity genotyping: a review of the literature and summary of patient experience
    Thomas P Moyer
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1079-94. 2009
    ....
  46. ncbi request reprint Venous thromboembolism epidemiology: implications for prevention and management
    John A Heit
    Division of Cardiovascular Diseases and Section of Hematology Research, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Semin Thromb Hemost 28:3-13. 2002
    ..To reduce venous thromboembolism incidence, improve survival, and prevent recurrence and complications, patients with these characteristics should receive appropriate prophylaxis...
  47. pmc Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients
    Carrie A Thompson
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:171-3. 2010
    ..Optimal management of AL patients with FX deficiency undergoing invasive procedures remains to be determined...
  48. ncbi request reprint Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies
    Anne Proven
    Division of Rheumatology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:467-75. 2004
    ..To assess the performance of 4 clotting assays for lupus anticoagulant (LA) detection, to determine the prevalence of LA and anticardiolipin antibodies (aCL), and to correlate LA and aCL prevalence with systemic disease and thrombosis...
  49. ncbi request reprint Risk factors for venous thromboembolism
    John A Heit
    Division of Cardiovascular Diseases, Section of Vascular Diseases, Division of Hematology, Section of Hematology Research, Stabile 610, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Chest Med 24:1-12. 2003
    ....
  50. ncbi request reprint Iliac arterial thrombosis after inguinal hernia repair
    Stephen F Van Buren
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1361-3. 2002
    ....
  51. ncbi request reprint Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders
    Richard D Press
    Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
    Arch Pathol Lab Med 126:1304-18. 2002
    ....
  52. ncbi request reprint Prevention of venous thromboembolism
    William Geerts
    Chest 128:3775-6. 2005
  53. ncbi request reprint Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
    Thromb Haemost 98:756-64. 2007
    ..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources...
  54. ncbi request reprint Prophylaxis for the thromboembolic disease--recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery?
    Clifford W Colwell
    J Arthroplasty 21:148-9; author reply 149. 2006
  55. ncbi request reprint Venous thromboembolism hospitalizations among American Indians and Alaska Natives
    W Craig Hooper
    Hematologic Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA
    Thromb Res 108:273-8. 2002
    ..2 per 100,000) and lowest in the Alaska region (16.1 per 100,000). These data indicate that the overall VTE rate for AI/ANs may not have only decreased, but appears lower than the reported rate for Caucasians...
  56. doi request reprint Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    William H Geerts
    Thromboembolism Program, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Chest 133:381S-453S. 2008
    ..We recommend that, on admission to the ICU, all patients be assessed for their risk of VTE, and that most receive thromboprophylaxis (Grade 1A)...
  57. ncbi request reprint Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism
    Frederick A Anderson
    Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Am J Hematol 82:777-82. 2007
    ..Given the existence of internationally-accepted evidence-based guidelines for prevention of VTE, research is required to establish if this patient population is receiving recommended VTE prophylaxis...
  58. ncbi request reprint Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    William H Geerts
    Thromboembolism Program, Sunnybrook and Women s College Health Sciences Centre, Room D674, 2075 Bayview Ave, Toronto, ON, Canada M4N 3M5
    Chest 126:338S-400S. 2004
    ..We recommend, on admission to the intensive care unit, all patients be assessed for their risk of VTE. Accordingly, most patients should receive thromboprophylaxis (Grade 1A)...
  59. ncbi request reprint The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients
    Niranjan Seshadri
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:27-34. 2005
    ....
  60. ncbi request reprint The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery
    John A Heit
    Arch Intern Med 162:1806-8. 2002

Research Grants19

  1. Individual Propensity to Venous Thrombosis
    John Heit; Fiscal Year: 2009
    ..However, the incidence of VTE has remained relatively constant at about 1 per 1000 since 1980. Clearly, better methods of targeting VTE prophylaxis are needed. ..
  2. Mayo Clinic Vascular Medicine Clinical Research Training Program
    John Heit; Fiscal Year: 2007
    ..In addition, this research will teach doctors how to discover new causes of diseases of arteries, veins and lymph vessels, as well as new ways to prevent and treat these diseases. ..
  3. RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITY
    John Heit; Fiscal Year: 2007
    ..This data will provide insights regarding the effect of new prophylaxis drugs on VTE incidence and why some but not most high-risk patients develop VTE, and test the effect of outpatient LMWH therapy on VTE recurrence. ..
  4. Individual Propensity to Venous Thrombosis
    John Heit; Fiscal Year: 2007
    ..However, the incidence of VTE has remained relatively constant at about 1 per 1000 since 1980. Clearly, better methods of targeting VTE prophylaxis are needed. ..
  5. RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITY
    John Heit; Fiscal Year: 2004
    ..Finally, the investigators will plan to extend their analysis of current VTE in relationship to use of standard heparin and low molecular weight heparin. ..
  6. RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITY
    John A Heit; Fiscal Year: 2010
    ..This study aims to prevent these deaths by identifying the individual person at high risk and preventing venous thromboembolism. ..